Trials / Completed
CompletedNCT00625768
Study of AS1409 in Patients With Either Metastatic Renal Cell Carcinoma or Metastatic Malignant Melanoma
A Phase I Study of AS1409 in Patients With Either Metastatic Renal Cell Carcinoma or Metastatic Malignant Melanoma
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 13 (actual)
- Sponsor
- Antisoma Research · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To determine the tolerability, safety, end-organ toxicity and maximum tolerated dose of AS1409 in single and repeated doses.
Detailed description
* To determine the tolerability, safety, end-organ toxicity and maximum tolerated dose (MTD) of AS1409 in single and repeated doses. * To determine biological responses to AS1409, including interferon-γ and IP-10 circulating concentrations. * To determine preliminary pharmacokinetics of AS1409. * To determine the immunogenicity of AS1409 * To explore the anti-tumour activity of AS1409.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AS1409 | Study drug |
Timeline
- Start date
- 2008-01-01
- Primary completion
- 2009-04-01
- Completion
- 2009-04-01
- First posted
- 2008-02-28
- Last updated
- 2009-08-25
Locations
4 sites across 2 countries: New Zealand, United Kingdom
Source: ClinicalTrials.gov record NCT00625768. Inclusion in this directory is not an endorsement.